Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Aclaris Therapeutics Inc’s stock clocked out at $1.56, up 1.96% from its previous closing price of $1.53. In other words, the price has increased by $1.96 from its previous closing price. On the day, 0.66 million shares were traded. ACRS stock price reached its highest trading level at $1.56 during the session, while it also had its lowest trading level at $1.5.
Ratios:
To gain a deeper understanding of ACRS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 28, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 168918352 and an Enterprise Value of 66088732. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.50 while its Price-to-Book (P/B) ratio in mrq is 1.17. Its current Enterprise Value per Revenue stands at 3.718 whereas that against EBITDA is -1.224.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.29, which has changed by 0.27868855 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 3.32%, while the 200-Day Moving Average is calculated to be -21.38%.
Shares Statistics:
It appears that ACRS traded 1.11M shares on average per day over the past three months and 2031690 shares per day over the past ten days. A total of 108.27M shares are outstanding, with a floating share count of 92.25M. Insiders hold about 14.81% of the company’s shares, while institutions hold 74.58% stake in the company. Shares short for ACRS as of 1752537600 were 7775760 with a Short Ratio of 6.99, compared to 1749772800 on 4843301. Therefore, it implies a Short% of Shares Outstanding of 7775760 and a Short% of Float of 8.559999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Aclaris Therapeutics Inc (ACRS) reflects the combined expertise of 6.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.07 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.28 and -$0.62 for the fiscal current year, implying an average EPS of -$0.53. EPS for the following year is -$0.63, with 6.0 analysts recommending between -$0.31 and -$0.87.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $1.29M. It ranges from a high estimate of $2.7M to a low estimate of $300k. As of the current estimate, Aclaris Therapeutics Inc’s year-ago sales were $2.77MFor the next quarter, 7 analysts are estimating revenue of $1.36M. There is a high estimate of $2.7M for the next quarter, whereas the lowest estimate is $600k.
A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $9.6M, while the lowest revenue estimate was $3.1M, resulting in an average revenue estimate of $5.86M. In the same quarter a year ago, actual revenue was $18.72MBased on 8 analysts’ estimates, the company’s revenue will be $9.93M in the next fiscal year. The high estimate is $44.7M and the low estimate is $900k.
